The performance of markers analysed in the trial in terms of showing the presence or the progression of disease in multiple patient populations may be indicative of the specific nature of the lung cancer assay to be developed and the regulatory authorisation pathway that
OncoCyte will pursue.
Currently,
OncoCyte is funding four trials of PanC-Dx in bladder, breast, and lung cancer.
Oncocyte are cells with prominent eosinophilic cytoplasm, but paradoxically clear cells dominate particularly in multinodular oncocytic hyperplasia.
USCN) of Wuhan, China, granting BioTime an option to license USCN's antibody-producing cell lines and certain related technology that may be used by BioTime and its subsidiary
OncoCyte Corporation for the large-scale manufacture of the antibody components of PanC-Dx.
In addition, the company's subsidiary,
OncoCyte Corporation elected Dr von Eschenbach to its boards of directors.
27 May 2014 - US biotech group BioTime Inc (NYSEAMEX:BTX) and its unit
OncoCyte Corporation said Tuesday that the latter would use its PanC-Dx diagnostic tests to perform comparative analysis of blood samples from healthy people and lung cancer patients provided by US Cornell University's Weill Cornell Medical College.
BioTime's HyStem product line is one of four components in our near-term revenue strategy, which also includes Hextend revenues, sales of stem cell research products (including the ACTCellerate cell lines and associated products), and planned near-term products being developed by our subsidiary
OncoCyte Corporation," said CEO Michael West.
targeting age-related vascular disease, and at
OncoCyte Corporation to deliver a toxic payload to cancerous tumors.
NYSE MKT: BTX) and BioTime's subsidiary
OncoCyte Corporation provided an update on the progress of development of PanC-Dx(TM), a novel blood-based diagnostic test utilizing molecular markers discovered at BioTime and
OncoCyte designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon.
28 January 2014 - US
OncoCyte Corp, a BioTime (NYSEMKT:BTX) subsidiary, said on Monday it had commenced clinical development in the US and China of its PanC-Dx markers in urothelial carcinoma (UC).
Shahin Ratli and Daylon James of the Weill Cornell Medical College is both elegant and useful, and may provide a means to generate virtually limitless quantities of high quality vascular cells," said
OncoCyte CEO Joseph Wagner.
BioTime will initially provide this technology to its majority owned subsidiary
OncoCyte Corporation, for its R&D related to genetically modified hES-derived vascular progenitors designed to target and destroy malignant tumors.
